Academic Journal
Προβολή σε EDS
Συνδεδεμένο Πλήρες Κείμενο

Immunoinformatics-Based Multi-Epitope Vaccine Targeting Helicobacter Pylori.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος: Immunoinformatics-Based Multi-Epitope Vaccine Targeting Helicobacter Pylori.
Συγγραφείς: Pasha AVK; Department of Medicinal Chemistry, TeMS.C., Islamic Azad University, Tehran, Iran., Esfandiyari M; Department of Medicinal Chemistry, TeMS.C., Islamic Azad University, Tehran, Iran., Parnian A; Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran., Mahboubi-Rabbani M; Department of Medicinal Chemistry, TeMS.C., Islamic Azad University, Tehran, Iran., Bayanati M; Phytochemistry Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Πηγή: Cancer reports (Hoboken, N.J.) [Cancer Rep (Hoboken)] 2026 Jan; Vol. 9 (1), pp. e70441.
Τύπος έκδοσης: Journal Article
Γλώσσα: English
Στοιχεία περιοδικού: Publisher: John Wiley & Sons, Inc Country of Publication: United States NLM ID: 101747728 Publication Model: Print Cited Medium: Internet ISSN: 2573-8348 (Electronic) Linking ISSN: 25738348 NLM ISO Abbreviation: Cancer Rep (Hoboken) Subsets: MEDLINE
Imprint Name(s): Original Publication: Hoboken, NJ : John Wiley & Sons, Inc., [2018]-
Ιατρικοί όροι (MeSH): Helicobacter pylori*/immunology , Bacterial Vaccines*/immunology , Computational Biology*/methods , Helicobacter Infections*/prevention & control , Helicobacter Infections*/immunology , Helicobacter Infections*/microbiology , Epitopes*/immunology, Vaccines, Subunit/immunology ; Flagellin/immunology ; Flagellin/chemistry ; Urease/immunology ; Urease/chemistry ; Cholera Toxin/immunology ; Epitopes, T-Lymphocyte/immunology ; Humans ; Molecular Docking Simulation ; Adjuvants, Immunologic ; Immunoinformatics
Περίληψη: Background: The rising global incidence of Helicobacter pylori-related diseases, particularly gastric cancer, underscores the urgent need for effective preventive vaccines, motivating the exploration of innovative immunoinformatic strategies to address this public health challenge.
Aims: The aim of this study was to design a multi-epitope subunit vaccine for Helicobacter pylori using an immunoinformatics approach. Specifically, the objectives were to predict potential epitopes from the flagellin B and urease B proteins, integrate the cholera toxin B subunit (CTB) as a mucosal adjuvant, and perform computational validation of the vaccine construct for antigenicity, stability, and interaction with immune receptors.
Methods: This study utilized an immunoinformatics approach to design a multi-epitope subunit vaccine, involving epitope prediction from flagellin B and urease B, integration of the cholera toxin B subunit (CTB) as a mucosal adjuvant, and computational validation through tools like VaxiJen, Phyre2, MolProbity, and HDOCK for antigenicity, structure, and docking analysis.
Results: The resulting vaccine construct comprises 406 amino acids with a molecular weight of 43 424.77 Da, exhibiting a predicted antigenic score of 1.0084, non-allergenic and non-toxic properties, and a stable physiochemical profile (instability index 23.51, GRAVY -0.425). Structural analysis suggested 99.1% (525/530) of residues in favored Ramachandran regions and 100.0% in allowed regions. Molecular docking with Toll-like receptor 5 (TLR5) indicated a superior docking score of -309.05 and a confidence score of 0.9601, outperforming TLR2 (-250.74), with 10 CTL epitopes (6 from flagellin B, 4 from urease B), 6 HTL epitopes, and 2 LBL epitopes linked by AAY, GPGPG, and KK linkers, respectively.
Conclusion: This research provides a computationally optimized vaccine design that shows potential for eliciting immune responses against H. pylori. Importantly, the findings remain entirely theoretical and require rigorous experimental validation in vitro and in vivo to assess their immunological relevance, safety, and efficacy before any translational or clinical application can be considered.
(© 2025 The Author(s). Cancer Reports published by Wiley Periodicals LLC.)
References: BMC Bioinformatics. 2010 Nov 22;11:568. (PMID: 21092157)
Acta Crystallogr D Biol Crystallogr. 2010 Jan;66(Pt 1):12-21. (PMID: 20057044)
J Biol Chem. 2009 Sep 11;284(37):25077-86. (PMID: 19617628)
Helicobacter. 2020 Apr;25(2):e12678. (PMID: 31880001)
Gut. 2004 Sep;53(9):1217-9. (PMID: 15306570)
Nat Biotechnol. 2019 Apr;37(4):420-423. (PMID: 30778233)
Nat Methods. 2011 Dec 25;9(2):173-5. (PMID: 22198341)
J Mol Biol. 2001 Jan 19;305(3):567-80. (PMID: 11152613)
J Mol Model. 2014 Jun;20(6):2278. (PMID: 24878803)
J Clin Invest. 2015 Aug 3;125(8):3297-302. (PMID: 26214524)
Vaccines (Basel). 2025 May 15;13(5):. (PMID: 40432137)
Biomed Res. 2019;40(2):87-95. (PMID: 30982804)
Infect Immun. 2005 Mar;73(3):1523-31. (PMID: 15731050)
Front Immunol. 2024 Aug 23;15:1432968. (PMID: 39247202)
BMC Infect Dis. 2023 Aug 19;23(1):543. (PMID: 37598157)
Front Immunol. 2024 Nov 28;15:1500921. (PMID: 39669583)
J Clin Gastroenterol. 2022 Feb 1;56(2):e98-e108. (PMID: 33405435)
Nat Protoc. 2015 Jun;10(6):845-58. (PMID: 25950237)
Bioinformatics. 2010 Jul 1;26(13):1608-15. (PMID: 20472543)
Vaccines (Basel). 2020 Nov 30;8(4):. (PMID: 33265930)
Sci Rep. 2017 Jan 20;7:40878. (PMID: 28106112)
Nat Protoc. 2020 May;15(5):1829-1852. (PMID: 32269383)
Nucleic Acids Res. 2025 Jan 6;53(D1):D20-D29. (PMID: 39526373)
World J Gastroenterol. 2023 Apr 28;29(16):2452-2468. (PMID: 37179585)
PLoS One. 2013 Sep 13;8(9):e74595. (PMID: 24058595)
Nucleic Acids Res. 2024 Jul 5;52(W1):W526-W532. (PMID: 38783079)
Curr Microbiol. 2017 Jul;74(7):863-869. (PMID: 28444418)
Bioinformatics. 1999 May;15(5):413-21. (PMID: 10366661)
Cureus. 2020 Dec 26;12(12):e12309. (PMID: 33520508)
Chirurgia (Bucur). 2024 Apr;119(eCollection):1-10. (PMID: 38657111)
Int J Clin Exp Pathol. 2014 Sep 15;7(10):6559-66. (PMID: 25400734)
Nucleic Acids Res. 2011 Jul;39(Web Server issue):W270-7. (PMID: 21624888)
Clin Exp Vaccine Res. 2012 Jul;1(1):50-63. (PMID: 23596577)
Bioinformatics. 2016 Feb 15;32(4):511-7. (PMID: 26515819)
Cancer Rep (Hoboken). 2026 Jan;9(1):e70441. (PMID: 41457476)
Expert Rev Vaccines. 2021 Aug;20(8):989-999. (PMID: 34139141)
Scand J Gastroenterol Suppl. 1991;187:39-46. (PMID: 1775923)
Trends Pharmacol Sci. 2024 Dec;45(12):1104-1118. (PMID: 39603961)
PLoS One. 2013 Sep 13;8(9):e73957. (PMID: 24058508)
PLoS One. 2025 Feb 07;20(2):e0318750. (PMID: 39919064)
Pathogens. 2024 May 08;13(5):. (PMID: 38787244)
Nucleic Acids Res. 2025 Jan 6;53(D1):D564-D574. (PMID: 39607707)
Nucleic Acids Res. 2025 Jan 6;53(D1):D56-D61. (PMID: 39558184)
Methods Mol Biol. 1999;112:531-52. (PMID: 10027275)
Helicobacter. 2005 Aug;10(4):345-52. (PMID: 16104951)
Expert Rev Mol Med. 2023 Jun 13;25:e23. (PMID: 37309681)
Bioinformatics. 2014 Jun 15;30(12):1771-3. (PMID: 24532726)
Gut Microbes. 2015;6(6):382-7. (PMID: 26727421)
Infect Drug Resist. 2023 Jun 15;16:3787-3805. (PMID: 37342435)
Aliment Pharmacol Ther. 1996 Apr;10 Suppl 1:57-64. (PMID: 8730260)
Chem Rev. 2020 Mar 25;120(6):3210-3229. (PMID: 31804810)
Cureus. 2023 Apr 6;15(4):e37205. (PMID: 37159779)
J Mol Biol. 1990 Oct 5;215(3):403-10. (PMID: 2231712)
Nat Rev Immunol. 2022 Apr;22(4):236-250. (PMID: 34312520)
Contributed Indexing: Keywords: Helicobacter Pylori; gastric cancer; gene sequences; immunodominant epitopes; immunogenicity; immunoinformatics; molecular docking; vaccine
Substance Nomenclature: 0 (Bacterial Vaccines)
0 (Vaccines, Subunit)
12777-81-0 (Flagellin)
EC 3.5.1.5 (Urease)
9012-63-9 (Cholera Toxin)
0 (Epitopes)
0 (Epitopes, T-Lymphocyte)
0 (Adjuvants, Immunologic)
Entry Date(s): Date Created: 20251229 Date Completed: 20251229 Latest Revision: 20260825
Update Code: 20260826
PubMed Central ID: PMC12745834
DOI: 10.1002/cnr2.70441
PMID: 41457476
Βάση Δεδομένων: MEDLINE
Περιγραφή
ISSN:2573-8348
DOI:10.1002/cnr2.70441